Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS

NCT03709680 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03709680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03709680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
May 24, 2019
Completion date
August 6, 2025
Enrollment
128 (actual)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine glioma, ewing sarcoma, medulloblastoma, neuroblastoma, rhabdoid tumor, rhabdomyosarcoma, solid tumors